These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28184022)

  • 1. Androgen receptor variants: another twist in the plot.
    Macoska JA
    Oncotarget; 2017 Mar; 8(10):16100. PubMed ID: 28184022
    [No Abstract]   [Full Text] [Related]  

  • 2. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.
    Suzuki H; Akakura K; Komiya A; Aida S; Akimoto S; Shimazaki J
    Prostate; 1996 Sep; 29(3):153-8. PubMed ID: 8827083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Words of wisdom. Re: Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Beuzeboc P
    Eur Urol; 2014 Dec; 66(6):1189-90. PubMed ID: 25587594
    [No Abstract]   [Full Text] [Related]  

  • 4. [New inhibitors of adrenal androgen synthesis enzymes].
    Mizokami A
    Nihon Rinsho; 2014 Dec; 72(12):2158-63. PubMed ID: 25518351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen metabolic genes in prostate cancer predisposition and progression.
    Makridakis NM; Buchanan G; Tilley W; Reichardt JK
    Front Biosci; 2005 Sep; 10():2892-903. PubMed ID: 15970543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid sidestep: evading androgen ablation by abiraterone.
    Sharifi N
    Clin Cancer Res; 2015 Mar; 21(6):1240-2. PubMed ID: 25432158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer.
    Atala A
    J Urol; 2020 Mar; 203(3):466. PubMed ID: 31793808
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
    Price DK; Franks ME; Figg WD
    J Urol; 2004 Feb; 171(2 Pt 2):S45-9; discussion S49. PubMed ID: 14713753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma.
    Culig Z; Hobisch A; Hittmair A; Peterziel H; Cato AC; Bartsch G; Klocker H
    Prostate; 1998 Apr; 35(1):63-70. PubMed ID: 9537601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism on androgen-independent progression of prostate cancer].
    Shimazaki J; Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1997 May; 55(5):1143-8. PubMed ID: 9155166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
    Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
    Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.
    Azzouzi AR; Cochand-Priollet B; Mangin P; Fournier G; Berthon P; Latil A; Cussenot O
    Eur J Endocrinol; 2002 Oct; 147(4):479-84. PubMed ID: 12370109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
    Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology of hormone-metabolic loci in prostate cancer.
    Makridakis NM; Reichardt JK
    Epidemiol Rev; 2001; 23(1):24-9. PubMed ID: 11588850
    [No Abstract]   [Full Text] [Related]  

  • 20. Androgen receptor as a target in androgen-independent prostate cancer.
    Balk SP
    Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.